Rare monosomy 7 and deletion 7p at diagnosis of chronic myeloid leukemia in accelerated phase.

Abstract

Clonal cytogenic evolution with the development of additional chromosomal abnormalities (ACAs) in chronic myelogenous leukemia (CML) is a marker for disease progression and is known to impact therapy and survival. The presence of ACAs has been shown to affect the responses to tyrosine kinase inhibitors (TKI) in patients with newly diagnosed CML in accelerated phase (CML-AP). We report a rare case of a CML patient who presented in CML-AP and was found to have multiple ACAs including monosomy 7, deletion 7p, trisomy 8, and an extra Philadelphia chromosome (Ph) in separate Ph-positive cell line, respectively. Six months after combined chemotherapy with TKI, the patient achieved a major cytogenetic response with disappearance of monosomy 7/deletion 7p with no major molecular response.

• Authors: Abdullah Alswied, Aseeb Rehman, Li-Wen Lai, Juanita Duran, Muhammad Sardar, Maria A Proytcheva
• Journal: Cancer genetics (Cancer Genet) Vol. 252-253 Pg. 111-114 (04 2021) ISSN: 2210-7762 [Print] United States
• PMID: 33497941 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2021. Published by Elsevier Inc.

Chemical References

• Antineoplastic Agents

Topics

• Adult
• Antineoplastic Agents (therapeutic use)
• Chromosome Deletion
• Chromosomes, Human, Pair 7
• Humans
• Karyotyping
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (diagnosis, drug therapy, genetics, pathology)
• Male